The Dermatology Digest has published a one-on-one interview with Patrick Urban, president of Merz Aesthetics, North America, giving the aesthetic dermatology trade press a direct line to one of the category's top regional executives.

The outlet did not syndicate the full Q&A text to its news feed, so Derm Field readers tracking injectables and device-maker strategy will need the original piece for the substance. The interview format itself signals what's on Merz's agenda for the North American market.

Why does this interview matter for dermatology practices?

Merz Aesthetics holds a portfolio position in neurotoxins and injectables that practices price against rivals every quarter. When a regional president goes on record with a trade outlet, the quotes typically preview pipeline priorities, supply commitments and commercial messaging that flow into practice purchasing decisions. The Dermatology Digest's decision to book Urban suggests the company wants that message in front of dermatologists now.

What can't we report yet?

Because the source feed delivered only the headline and byline attribution, Derm Field can't responsibly quote Urban or characterize his statements. We won't paraphrase an interview we haven't read in full, and we won't project portfolio moves onto a company that hasn't stated them here.

Where to look next

Practitioners should watch for follow-up coverage if Urban's remarks touch on toxin supply, pricing or new indication timing — the details that move practice economics. Derm Field will update this story once the full interview text is accessible.